Singapore's millionaires chase longevity and well-being as latest must-haves
Living longer has become the latest pursuit of the rich as they rethink what it means to live well while planning for the future, said a new report.
It found that rising geopolitical tensions and economic uncertainty have prompted the well-off to reassess their lives and try to balance present-day enjoyment with preparation for the future.
The report from Swiss bank Julius Baer, which studied the lives and consumption trends of millionaires in 15 countries, noted a near-universal preoccupation with financial well-being and physical health.
Around 60 per cent of the rich in the Asia-Pacific said their discretionary health spending had risen over the past year, compared with 40 per cent or so in Europe and North America.
'Health really is wealth, and investments in healthcare are seen as the latest must-haves,' the report said.
Healthcare and wellness are the 'new luxury' in the Asia-Pacific, where 63 per cent said they were concerned about their health and well-being.
Actions range from adopting healthier lifestyles through regular exercise and a good diet, to exploring cutting-edge interventions such as gene therapy and cryogenic treatments.
Gene therapy aims to treat or prevent disease by modifying a person's genes, while cryogenic treatments involve applying extreme cold to preserve biological materials or treat certain conditions.
Living longer is just one side of this coin; living better comes into it as well, with lifestyle expenses in the Asia-Pacific outpacing most regions, notably in high-end women's clothes, five-star hotels and fine dining.
The region also saw a marked increase in leisure trips compared with business travel.
Julius Baer said the post-pandemic business travel boom has slowed as working patterns settle into a hybrid model.
The bank is also witnessing 'a demographic group that is fully embracing life and new experiences again after Covid-19 and subsequent crises'.
Faced with potentially longer lives, most millionaires here and in the Asia-Pacific are willing to adjust wealth strategies, rebalance portfolios and re-evaluate retirement goals. They are also more open to creating long-term care plans.
Globally, wealth creation remains the top objective.
'Our research shows that 70 per cent of high-net-worth individuals in our survey reported increased assets in the past 12 months. They are once again looking to build on their recent increases,' the report said.
Wealth preservation has gained ground, particularly in North America and Europe, where a more conservative approach to investment now prevails, reflecting increased risk aversion amid global uncertainty.
By contrast, respondents in the Asia-Pacific, Middle East and Latin America are open to more risk, embracing higher-risk strategies and diversifying their portfolios to align with personal values and emerging global trends.
Equities remain the preferred asset class in the Asia-Pacific, followed by real estate and cash.
A separate study by Manulife Singapore and Forbes Insights revealed that wealth is no guarantee of peace of mind when it comes to ageing and long-term health.
While most of the high-net-worth individuals in Singapore agreed that 'nothing is more important than health', fewer than half are confident they will remain healthy and active after retirement.
'For our customers, wealth is no longer the goal in itself – it's the means to protect the lifestyle, health and choices they've worked so hard to build,' said Mark Czajkowski, chief marketing officer at Manulife Singapore.
Many are uncertain about their financial readiness for health-related challenges. Those acting to live longer and better are turning to technologies such as wearables, as well as diet and exercise, consulting health experts and employing state-of-the-art insurance solutions.
An openness to experimental wellness practices like intermittent fasting, cryotherapy and sleep optimisation has also emerged, reflecting an evolving approach to healthy ageing, the study said. - The Straits Times/ANN
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
37 minutes ago
- The Star
Global vaccination stalling, kids at risk of preventable diseases
Efforts to vaccinate children globally have stalled since 2010, leaving millions vulnerable to tetanus, polio, tuberculosis and other diseases that can be easily prevented. Protection from measles in particular dropped in 100 countries between 2010 and 2019, unravelling decades of progress, including in rich countries that had previously eliminated the highly infectious disease, according to a new analysis of global vaccination trends published Tuesday in the journal Lancet. "After clean water, vaccination is the most effective intervention for protecting the health of our children,' said Helen Bedford, a professor of children's health at University College London, who was not connected to the warned there has been a small but worrying rise in the number of parents skipping vaccination for their children in recent years, for reasons including misinformation. In Britain, Prof Bedford said that has resulted in the largest number of measles recorded since the 1990s and the deaths of nearly a dozen babies from whooping cough. Vaccination rates in the United States are also falling, and exemptions from vaccinations are at an all-time high. After the World Health Organisation (WHO) established its routine immunisation program in 1974, countries made significant efforts to protect children against preventable and sometimes fatal diseases; the program is credited with inoculating more than four billion children, saving the lives of 154 million worldwide. Since the programme began, the global coverage of children receiving three doses of the diphtheria-tetanus-whooping cough vaccine nearly doubled, from 40% to 81%. The percentage of kids getting the measles vaccine also jumped from 37% to 83%, with similar increases for polio and after the Covid-19 pandemic, coverage rates dropped, with an estimated 15.6 million children missing out on the diphtheria-tetanus-whooping cough vaccine and the measles 16 million children failed to get vaccinated against polio and nine million missed out on the TB vaccine, with the biggest impact in sub-Saharan study was funded by the Bill & Melinda Gates Foundation and Gavi, The Vaccine Alliance. Protection from measles, which is preventable through vaccination, has dropped in 100 countries between 2010 and 2019. Photo: CARLOS SANCHEZ/Reuters Public protection In a pledge of support for Gavi, the British government announced recently it will give £1.25bil (RM7.26bil) between 2026 and 2030 to the international vaccine said the money will help Gavi protect up to 500 million children in some of the world's poorest countries from diseases including meningitis, cholera and measles, potentially saving eight million lives. Health advocates welcomed the money but some noted it is less than the £1.65bil Britain (RM9.58bil) pledged over the five years from 2020. Researchers at the Institute for Health Metrics and Evaluation at the University of Washington, who conducted the Lancet analysis, noted that more than half of the world's 15.7 million unvaccinated children live in just eight countries in 2023: Nigeria, India, Congo, Ethiopia, Somalia, Sudan, Indonesia and Brazil. Since President Trump has begun to withdraw the US from the WHO and dismantled the US Agency for International Aid, public health experts have warned of new epidemics of infectious diseases. The researchers said it was too early to know what impact recent funding cuts might have on children's immunisation rates. The WHO said there had been an 11-fold spike in measles in the Americas this year compared to infections doubled in the European region in 2024 versus the previous year and the disease remains common in Africa and South-East Asia. "It is in everyone's interest that this situation is rectified,' said Dr David Elliman, a paediatrician who has advised the British government, in a statement. "While vaccine-preventable infectious diseases occur anywhere in the world, we are all at risk.' – AP
The Sun
a day ago
- The Sun
AstraZeneca plans US$50b US move amid tariff threat
WASHINGTON: AstraZeneca plans to spend US$50 billion (RM212 billion) to expand manufacturing and research capabilities in the US by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to President Donald Trump's tariff policy. The investment will fund a new drug manufacturing facility in Virginia and expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, it said in a statement. It will also upgrade the Anglo-Swedish drugmaker's US clinical trial supply network and support ongoing investment in novel medicines. On Monday, AstraZeneca said the expansion supports its ambition to reach US$80 billion in annual revenue by 2030, with half coming from the US. The US accounted for more than 40% of AstraZeneca's annual revenue in 2024, and the company had been prioritising the market – the world's largest, worth US$635 billion – before Trump's return to office. The move to scale up its US footprint is the latest by a drugmaker as Trump threatens to impose import tariffs on the industry and seeks to boost domestic manufacturing. The sector has historically been spared from trade disputes. Trump has called on pharma companies to make more of the medicines they sell in the US within the country, rather than importing active ingredients or finished medicines. He is also pushing for prices in the US to fall to what other countries pay. CEO Pascal Soriot announced the plans in Washington, saying he believes that drug prices need to rise elsewhere and 'equalize' with other countries effectively contributing more to research and development costs. 'The US cannot build or carry the cost of R&D for the entire world,' he said. US Commerce Secretary Howard Lutnick's department is leading a probe into pharmaceutical imports that could pave the way for new tariffs. 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness,' said Lutnick in a statement issued by AstraZeneca. While Trump has repeatedly threatened tariffs on the sector, he signalled earlier this month that companies would be given a year to 18 months to 'get their act together' before any levies take effect. The company said that the timing and location of the announcement was linked to the US policy environment, though some of the spending would have occurred regardless so that the infrastructure for future medicines was in place. The pledge is in addition to the US$3.5 billion in investments the company announced in November 2024, the statement said. The US$50 billion pledge matches the commitment announced by Swiss rival Roche in April and follows new spending plans unveiled this year by Eli Lilly & Co, Johnson & Johnson , Novartis, and Sanofi. Also present at the announcement was Virginia State Governor Glenn Youngkin, a vocal Trump ally who has defended the administration's tariff policies. The new Virginia facility – the company's largest single manufacturing investment – will produce active ingredients for AstraZeneca's experimental weight-loss medicines, including its oral GLP-1 candidate and an oral PCSK9 inhibitor for cholesterol management, it said. The company said the investment could create tens of thousands of new jobs, but declined to give specifics. It employs about 18,000 people in the US and has a global workforce of about 90,000. – Reuters
Sinar Daily
a day ago
- Sinar Daily
Health Ministry to deploy AI to detect dengue hotspots early
The predictive AI tool is designed to pinpoint high-risk areas before case numbers rise, enabling more targeted intervention. 22 Jul 2025 03:48pm Health Minister Datuk Seri Dr Dzulkefly Ahmad - BERNAMA FILE PIX KUALA LUMPUR - The Health Ministry is developing an artificial intelligence (AI) system to predict and identify dengue hotspots, as part of efforts to strengthen early detection and outbreak response. Health Minister Datuk Seri Dr Dzulkefly Ahmad told the Dewan Rakyat today that the predictive AI tool is designed to pinpoint high-risk areas before case numbers rise, enabling more targeted intervention. "Dengue-related deaths have now exceeded Covid-19 fatalities. So far this year, there have been 21 dengue deaths, compared to just one from Covid-19," he said during the question-and-answer session. However, he noted the situation has improved from last year, when Malaysia recorded over 83,000 dengue cases and 117 deaths. Dr Dzulkefly was responding to a supplementary question from Datuk Dr Ahmad Yunus Hairi (PN-Kuala Langat), who asked about measures to tackle recurring dengue outbreaks. He said Selangor continues to record the highest number of cases, followed by Kuala Lumpur. He also highlighted the effectiveness of the Wolbachia mosquito programme, which is being implemented in 45 localities. The programme has achieved success rates of between 45 per cent and 100 per cent in suppressing Aedes mosquito populations, he added. Regarding dengue vaccine development, Dr Dzulkefly said that research and development efforts are ongoing at Universiti Malaya under the ministry's direction. - BERNAMA More Like This
